## Alberto Aimo

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1978607/alberto-aimo-publications-by-year.pdf

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,470 101 20 35 h-index g-index citations papers 2,489 5.07 154 5.1 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
101	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis <i>European Heart Journal Cardiovascular Imaging</i> , <b>2022</b> ,	4.1	1
100	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis <i>Scientific Reports</i> , <b>2022</b> , 12, 4691	4.9	0
99	Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1288-1303	15.1	3
98	Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis <i>Heart Failure Reviews</i> , <b>2022</b> , 1	5	2
97	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond Cardiac Failure Review, <b>2022</b> , 8, e12	4.2	1
96	Pirfenidone as a novel cardiac protective treatment. Heart Failure Reviews, 2021, 1	5	3
95	Imaging predictors of incident heart failure: a systematic review and meta-analysis. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 378-387	1.9	3
94	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e02035	58	6
93	Remote Ischemic Conditioning in Ischemic Stroke and Myocardial Infarction: Similarities and Differences. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 716316	4.1	1
92	Heart diseases (autonomic dysfunctions) Myocardial innervation imaging: 123I-MIBG planar scintigraphy and SPECT <b>2021</b> ,		
91	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 881-890	5	10
90	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 1067-1076	3.9	20
89	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. <i>Journal of Chemotherapy</i> , <b>2021</b> , 33, 435-439	2.3	2
88	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 497	<b>′</b> £94	6
87	Echocardiography versus computed tomography and cardiac magnetic resonance for the detection of left heart thrombosis: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1697-1703	6.1	5
86	COVID-19 and myocarditis: a systematic review and overview of current challenges. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	28
85	Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury. <i>Journal of Cardiovascular Pharmacology</i> , <b>2021</b> , 77, 332-333	3.1	1

## (2021-2021)

84	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. <i>Scientific Reports</i> , <b>2021</b> , 11, 5940	4.9	1
83	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2021, 1	5	11
82	Exercise tolerance and quality of life in patients with known or suspected coronary artery disease. <i>Quality of Life Research</i> , <b>2021</b> , 30, 2541-2550	3.7	О
81	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13598	4.6	3
80	Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3014-3025	3.7	2
79	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. <i>International Journal of Cardiology</i> , <b>2021</b> , 333, 45-50	3.2	3
78	Subclinical cardiac damage in cancer patients before chemotherapy. Heart Failure Reviews, 2021, 1	5	О
77	Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13464	4.6	9
76	A simple echocardiographic score to rule out cardiac amyloidosis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13449	4.6	6
75	Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13400	4.6	2
74	Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 2245-2255	2.5	1
73	Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 2037-2047	2.5	1
<del>7</del> 2	Use of biomarkers to diagnose and manage cardiac amyloidosis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 217-230	12.3	12
71	The relationship between blood pressure and risk of atrial fibrillation: a Mendelian randomization study. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	6
70	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. <i>JACC: Case Reports</i> , <b>2021</b> , 3, 450-454	1.2	О
69	Response to the comment by Dr Yarlas. European Journal of Clinical Investigation, 2021, 51, e13652	4.6	
68	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2021</b> , 58, 530-545	9.4	2
67	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2021, 1	5	4

66	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	3
65	The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1458-1467	12.3	6
64	Vericiguat for Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2021, 23, 144	4.2	6
63	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. <i>International Journal of Cardiology</i> , <b>2021</b> , 336, 98-104	3.2	O
62	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2021</b> , 1-7	2.7	1
61	The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis?. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 1877-1878	8.4	
60	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1577-1596	12.3	7
59	Sex-related differences in ventricular remodeling after myocardial infarction. <i>International Journal of Cardiology</i> , <b>2021</b> , 339, 62-69	3.2	1
58	The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	1
57	Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 2400-2403	1.2	1
56	Cardiac magnetic resonance in patients with muscular dystrophies. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320923052	3.9	4
55	Cardiovascular disease and COVID-19: les liaisons dangereuses. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 1017-1025	3.9	14
54	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320927610	3.9	9
53	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 80, 66-72	3.9	16
52	Cardiovascular magnetic resonance for the diagnosis and management of heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , <b>2020</b> , 1	5	4
51	Intracoronary Delivery of Mitochondria to Prevent Ischemia-Reperfusion Injury: Challenging Pathway From Bench to Bedside. <i>JACC Basic To Translational Science</i> , <b>2020</b> , 5, 208	8.7	1
50	Safety and efficacy of levosimendan in patients with cardiac amyloidosis. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 80, 114-116	3.9	1
49	The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , <b>2020</b> , 307, 180-186	3.2	4

48	Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. <i>Pharmacological Research</i> , <b>2020</b> , 155, 104694	10.2	27
47	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. <i>International Journal of Cardiology</i> , <b>2020</b> , 307, 187-192	3.2	5
46	Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Letter regarding the article <b>B</b> aseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trialS <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1934-1	12.3 935	
45	Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 121-129	1.9	2
44	Thyroid, Heart Failure, and Neuroendocrine Activation <b>2020</b> , 301-309		1
43	Magnetic Resonance to Diagnose Cardiac Amyloidosis: Is it Already Time to Discard Contrast Agents?. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 1293-1294	8.4	1
42	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 237-243	2.7	4
41	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2078-2088	12.3	15
40	Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. <i>JACC:</i> Cardiovascular Imaging, <b>2020</b> , 13, 909-920	8.4	47
39	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 199-206	7	4
38	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1795-1807	15.1	26
37	Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13362	4.6	144
36	Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , <b>2020</b> , 22, 84	6.9	10
35	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. <i>International Journal of Cardiology</i> , <b>2020</b> , 301, 190-194	3.2	7
34	Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 494-510	3.9	56
33	Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article Groponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. S European Journal of Heart Failure,	12.3	
32	Management of complications of cardiac amyloidosis: 10 questions and answers. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320920756	3.9	5
31	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. <i>International Journal of Cardiology</i> , <b>2019</b> , 296, 91-97	3.2	30

30	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1751-1759	3.9	17
29	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. <i>International Journal of Cardiology</i> , <b>2019</b> , 293, 137-142	3.2	13
28	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706	59.5	75
27	Cardiac troponins as biomarkers for cardiac disease. <i>Biomarkers in Medicine</i> , <b>2019</b> , 13, 325-330	2.3	20
26	Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 782-794	7.9	52
25	sST2 for Outcome Prediction in Acute[Heart[Failure: Which Is the Best Cutoff?. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 478-479	15.1	3
24	Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2193-2203	15.1	49
23	Letter by Aimo et al Regarding Article, "Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies". <i>Circulation</i> , <b>2019</b> , 140, e816-e817	16.7	
22	What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas. <i>JACC: Case Reports</i> , <b>2019</b> , 1, 657-662	1.2	1
21	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , <b>2019</b> , 277, 166-172	3.2	15
20	Sex-related differences in chronic heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 255, 145-151	3.2	31
19	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. <i>Circulation</i> , <b>2018</b> , 137, 286-297	16.7	102
18	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 889-8	<b>9</b> 59	11
17	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , <b>2018</b> , 250, 195-200	3.2	17
16	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 1419-1430	3.9	7
15	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 273, 136-140	3.2	8
14	sST2 Predicts Outcome in Chronic[Heart[Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2309-2320	15.1	73
13	Low-Thrombogenicity Mechanical Heart Valves: Which Antithrombotic Strategy?. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1878-1879	15.1	1

## LIST OF PUBLICATIONS

12	heart failure. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 324-330	3.2	13
11	Therapies for cardiac light chain amyloidosis: An update. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 152-160	3.2	15
10	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. <i>International Journal of Cardiology</i> , <b>2018</b> , 267, 188-192	3.2	28
9	Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1701-1709	12.3	13
8	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, <b>2017</b> , 5, 287-296	7.9	71
7	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 735-	7/43	17
6	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 1718-1724	3.9	1
5	How to take arms against central apneas in heart failure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2017</b> , 15, 743-755	2.5	2
4	Cardiac light-chain deposition disease relapsing in the transplanted heart. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 135-137	2.7	1
3	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 280-286	7.9	89
2	The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocitic leukaemia. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 997-9	3.2	2
1	Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. <i>World Journal of Cardiology</i> , <b>2015</b> , 7, 621-32	2.1	27